Announced Mon, 13 Jul · 18:40 IST
USFDA Warning Letter to Clinical Investigator at Bioequivalence Facility
Regulatory & Legal View source PDF
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+2.7%1-day move
₹830.00
prior close
₹820.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5-0.6-0.2+0.5+2.7+1.5-0.6+2.4+0.4-3.0————
Up moveDown movePending
AI summary
Alembic Pharma informed that USFDA issued a Warning Letter on 10 Jul 2026 to a Clinical Investigator associated with a bioequivalence study at its Vadodara facility. The letter pertains to Informed Consent Form observations and not data integrity. Company says no restrictions on facility operations and no material financial impact identified. Coordinating with investigator to respond to USFDA within stipulated timeline.
Likely market impact
Negative regulatory signal, but limited direct impact as warning is to the investigator, not the facility. Data integrity not questioned. Watch response outcome.